Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

2017
April
May
June
July
August
September
October
November
December
Select month
20182019

2017

-

December

Date
Title
Category
Company
December 1, 2017
New patient mobility agreement enables childless couple to get treament in both Malmö and Copenhagen
Life Science
Medicon Valley Alliance
December 1, 2017
InDex Pharmaceuticals reports new mechanism of action data for cobitolimod
Pharma
InDex Pharmaceuticals
December 5, 2017
Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study
Pharma
AbbVie
December 5, 2017
Always, always have the buyer’s perspective when crafting your message
Life Science
Ideon Science Park
December 5, 2017
Spago Nanomedical select ChemConnection for SpagoPix production to supply clinical trials
Life Science
Spago Nanomedical
December 5, 2017
IMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenström's Macroglobulinemia Met Primary Endpoint
Pharma
AbbVie
December 6, 2017
Lund University ranked 46th best place to study life sciences worldwide
Life Science
Medicon Valley Alliance
December 6, 2017
Novo Nordisk Receives FDA Approval of OZEMPIC® (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes
Pharma
Novo Nordisk Pharmatech A/S
December 6, 2017
Four Cluster Companies Get Innovation Reward
Life Science
Oslo Cancer Cluster
December 11, 2017
Lucia celebration at Ideon Science Park
Ideon Science Park
December 11, 2017
IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
Pharma
AbbVie
December 12, 2017
IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients
Pharma
AbbVie
December 12, 2017
IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition
Pharma
AbbVie
December 13, 2017
AbbVie Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint
Pharma
AbbVie
December 15, 2017
Municipality of Ballerup in top 3 of leading life science municipalities in greater Copenhagen
Life Science
Medicon Valley Alliance
December 18, 2017
Oncoinvent With New Lab and Bright Future
Life Science
Oslo Cancer Cluster

Nordic Life Science - Insight

NLS Insight's goal is to assist the Nordic regions leading innovators in targeting business collaborations, parnership opportunities and investment potential.

info@nlsinsight.com
+47 69 51 02 XX
Olaf Helsets vei 5, 0694 Oslo
Mail iconinfo@nlsinsight.com
Phone Icon+47 69 51 01 94
Adress IconOlaf Helsets vei 5, 0694 Oslo
Facebook icon
Twitter icon
LinkedIn icon
Privacy policy
Subscribe to
our newsletters

Designed by Horn Digital Media 2019